Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series <span class="so-article-trans-title" dir="auto"> Translated title: Homöopathische Behandlung bei Symptomen im Zusammenhang mit COVID-19: eine Fallserie </span>

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Severe acute respiratory syndrome due to coronavirus 2 (SARS CoV-2) is a novel infectious disease, which has quickly developed into a pandemic. The spectrum of COVID-19 symptoms is broad, ranging from a mild, self-limiting respiratory tract illness to severe progressive pneumonia, multi-organ failure and possible death. Despite much effort and multiple clinical trials, there are, to date, no specific therapeutic agents to treat or cure the coronavirus infection.

Case Reports

The present paper presents 5 cases of patients with moderate to severe COVID-19 infections, 2 of them hospitalized in the intensive care unit, who were successfully treated with homeopathy.

Results

All 5 patients responded to homeopathic treatment in an unexpectedly short time span, improving both physically and mentally.

Conclusion

The present case series emphasizes the rapidity of response among moderate to severely ill patients to homeopathic treatment, when conventional medical options have been unable to relieve or shorten the disease. The observations described should encourage use of homeopathy in treating patients with COVID-19 during the acute phase of the disease.

Zusammenfassung

Hintergrund

Das schwere akute respiratorische Syndrom bei Coronavirus-2-Infektion (Corona virus 2 severe acute respiratory syndrome, SARS CoV-2) ist eine neuartige Infektionskrankheit, die sich rasch zu einer Pandemie entwickelt hat. Das Spektrum der Symptome bei COVID-19 ist breit und reicht von einer leichten, selbstlimitierenden Atemwegserkrankung bis zu einer schweren progredienten Lungenentzündung, Multiorganversagen und möglichem Tod. Trotz enormer Anstrengungen und zahlreicher klinischer Studien existieren bis jetzt keine spezifischen therapeutischen Wirkstoffe zur Behandlung oder Heilung einer Infektion mit dem Coronavirus.

Fallberichte

Die vorliegende Arbeit berichtet über 5 Fälle von Patienten mit mittelschwerer bis schwerer COVID-19-Infektion, davon 2 intensivmedizinisch behandelte Patienten, die erfolgreich homöopathisch behandelt wurden.

Ergebnisse

Alle 5 Patienten sprachen nach unerwartet kurzer Zeit auf die homöopathische Behandlung an und zeigten sowohl eine körperliche als auch eine geistige

Related collections

Most cited references 10

Record: found
Abstract: found
Article: not found

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang, Yeming Wang, Xingwang Li … (2020)

Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.

0 comments Cited 22903 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: found

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

Dawei Wang, Bo Hu, Fangfang Zhu … (2020)

In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited.

0 comments Cited 11220 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen, Min Zhou, Xuan Dong … (2022)

Summary Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020. Findings Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market. The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient). According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax. 17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure. Interpretation The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection. Funding National Key R&D Program of China.

0 comments Cited 9768 times – based on 0 reviews      Review now

All references

Author and article information

Journal

Journal ID (nlm-ta): Complement Med Res

Journal ID (iso-abbrev): Complement Med Res

Journal ID (publisher-id): CMR

Title: Complementary Medicine Research

Publisher: S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )

ISSN (Print): 2504-2092

ISSN (Electronic): 2504-2106

Publication date (Electronic): 14 September 2021

Publication date PMC-release: 14 September 2021

Pages: 1-6

Affiliations

[1] ^aInternal Medicine Division, Shaare Zedek Medical Center, Jerusalem, Israel

[2] ^bCenter for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

[3] ^cPulmonary Institute, Shaare Zedek Medical Center, Jerusalem, Israel

[4] ^dIntensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel

[5] ^eDynamis, London, United Kingdom

Author notes

*Menachem Oberbaum, oberbaum@ 123456szmc.org.il

[1]

All remedies were supplied as 30C potencies. A single dose was 3 globules.

Article

Publisher ID: cmr-0001

DOI: 10.1159/000517924

PMC ID: 8678262

PubMed ID: 34521083

SO-VID: 51e709a3-9da6-4454-8607-722cb0c8ca6f

License:

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

History

Date received : 7 March 2021

Date accepted : 17 June 2021

Page count

References: 14, Pages: 6

Comments

Comment on this article

Cited by 2

See all cited by

Most referenced authors 1,699

See all reference authors

- Version 1

Call for Papers: Epidemiology of CKD and its Complications

Submit here by August 31, 2024

Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series Translated title: Homöopathische Behandlung bei Symptomen im Zusammenhang mit COVID-19: eine Fallserie

Read this article at